How to Value a Medical Billing Company in 2026

Medical billing is one of the quiet success stories of the healthcare services world. While everyone talks about AI disruption, the physician-focused billing companies I track keep trading at 5-9x EBITDA, with the best ones fetching double digits. R1 RCM went private in 2024 at an enterprise value north of $8 billion. Waystar went public at a $3.5B valuation. The buyers are paying real money because the underlying economics are excellent — once you understand what makes one billing company worth 5x and another worth 9x.

I've advised on several mid-market billing company sales, and the range of outcomes is wider than almost any services business I work with. Two companies with identical $3M revenue can sell for $6M and $16M depending on a handful of factors. Let me walk through what actually drives these deals.

The Economics That Make Billing Attractive

Physician billing companies typically charge 5-9% of collections as their fee, with specialty practices (anesthesia, radiology, pathology, emergency medicine) on the higher end. That fee structure is why buyers love the space: revenue is contractually recurring, tied to physician collections that rarely drop materially year-over-year, and gross margins run 55-70% once you hit scale.

A well-run physician billing company with $3M in revenue should produce $750K-$900K in EBITDA — roughly 25-30% margins. Below 20% margins, buyers start asking why. Above 35%, they start asking whether you're under-investing in compliance and technology (a legitimate concern in 2026 with payer downcoding getting more aggressive).

The base multiple for a $500K-$2M EBITDA physician billing company is 5-7x EBITDA. Cross $2M in EBITDA and you're in 7-9x territory. Platform deals with proprietary technology and multi-specialty reach trade at 9-12x. Outside that range, you're either an add-on (4-5x) or a genuine strategic (12x+).

Client Concentration Kills Multiples

The single biggest variable in billing company valuation is client concentration. If your top client is 40% of revenue, you're getting 4-5x EBITDA regardless of how good your operation is. Buyers have been burned too many times by billing companies that lost their anchor client six months after closing.

The rule I use: no single client should exceed 15% of revenue, and your top five clients combined shouldn't exceed 40%. Hit those thresholds and you unlock the upper end of the multiple range. A 50-client book with the largest at 8% is worth meaningfully more than a 10-client book where the top three are 60% combined — even if the revenue and EBITDA are identical.

Specialty mix matters too. Anesthesia and radiology groups are sticky because switching billers is painful and the specialty-specific coding expertise is hard to replace. Primary care and internal medicine clients churn more easily. A book heavy in sticky specialties commands a 1-2 turn premium over a general book.

Technology Is Now a Discrete Value Driver

Five years ago, billing companies were mostly about labor arbitrage and process discipline. Today, technology is a distinct line item in every diligence process I've seen. Buyers want to know: are you running on a modern RCM platform, are you licensing third-party software, or have you built something proprietary?

Companies running entirely on Kareo, AdvancedMD, or athenaCollector get base multiples — the technology isn't yours, so it doesn't create defensibility. Companies that have built workflow automation layers on top of those platforms (claim scrubbing, denial management bots, patient balance follow-up) get a half-turn to full-turn premium. Companies with genuine proprietary RCM platforms — rare at the sub-$5M EBITDA level — get paid like technology businesses, often 2-4 turns higher.

This matters for your exit planning. If you're 2-3 years out, investing $200K-$400K in building automation and documenting it as proprietary IP can return 5-10x that investment at sale. Related: how technology changes valuation multiples across healthcare services.

Who's Actually Buying

The buyer pool has shifted meaningfully since 2020. The most active acquirers I've seen in the mid-market physician billing space include:

• PE-backed platforms: Coronis Health (Audax), Ventra Health (Webster Capital), Infinx (Norwest), and Savista (New Mountain) have all been rolling up regional billing companies at 6-9x EBITDA.
• Strategic RCM players: R1 RCM, Waystar, and Ensemble Health Partners occasionally buy billing companies as channel or specialty extensions, typically paying 8-11x for clean assets.
• Specialty consolidators: Anesthesia-focused (NAPA, US Anesthesia Partners), radiology-focused (Radiology Partners), and pathology groups sometimes acquire their billers directly.
• Search funds and independent sponsors: Active at the $500K-$1.5M EBITDA level, paying 4-6x with heavy seller financing and rollover equity.

Knowing which pool you're marketing to shapes the process. PE platforms move fast and pay well but insist on 3-5 year earnouts. Strategics pay highest but have longer diligence cycles. Search funders pay less but offer clean exits.

What Kills Billing Company Deals

I've seen more billing deals fall apart in diligence than close. The usual suspects:

Dirty contracts. If half your client agreements are handshake deals, month-to-month arrangements, or expired multi-year contracts running on autopilot, buyers will discount 10-20% of revenue in their model. Get every client on a signed, current agreement with assignment language before going to market.

Compliance gaps. HIPAA, SOC 2, and payer audit history matter. A single unresolved OIG inquiry or payer clawback demand can nuke a deal entirely. Buyers' attorneys pull audit trails, and surprises are fatal.

Key person risk. If you're the only one who knows how to run the denial management process, your value drops. Document workflows, cross-train supervisors, and build a management team that can operate without you for 30 days.

Revenue quality questions. Buyers will ask for 36 months of client-level revenue detail. If clients are churning and you're replacing them with new logos to keep total revenue flat, the underlying trend shows up in cohort analysis. Be honest about it or it blows up in diligence. See also: how to present clean adjusted EBITDA.

Moving the Multiple Higher

If you're planning to sell in 18-36 months, focus on these levers in order of impact:

Diversify the client book. Nothing moves multiples like getting concentration down. Add 15-20 small practices even at lower margins — the multiple expansion on the whole business is worth more than the margin hit.

Lock in multi-year contracts. Three-year minimums with auto-renewal and 90-day termination notice are the gold standard. Buyers will pay for contracted revenue in a way they won't for at-will arrangements.

Document your technology stack. Whatever you've built — even if it's spreadsheet-based workflow management — write it up as a proprietary methodology with training materials. Buyers pay for transferable IP.

Build a pipeline story. A billing company with $500K in signed but not-yet-live contracts and a documented sales process is worth a turn more than one relying on referrals alone. Growth visibility matters.

The Bottom Line

Medical billing for physician practices is one of the most attractive healthcare services niches for M&A in 2026. The recurring fee model, high gross margins, and active PE consolidation create real opportunity for owners who prepare well. The difference between a 5x and a 9x exit isn't luck — it's client diversification, technology defensibility, contract quality, and clean compliance. Start working on those 24 months before you want to sell and the multiple takes care of itself.